{"title":"Certolizumab pegol: a new option for rheumatoid arthritis","authors":"Margaret HY Ma MBBS, BSc, MRCP, MSc, Ernest HS Choy MD FRCP","doi":"10.1002/fps.57","DOIUrl":null,"url":null,"abstract":"<p>Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"10 4","pages":"15-20"},"PeriodicalIF":0.0000,"publicationDate":"2009-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.57","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd.
Certolizumab pegol:类风湿关节炎的新选择
类风湿性关节炎(RA)是英国医疗保健的一个重大负担。新的生物疗法有先进的治疗方法，但对NHS来说成本很高。Certolizumab pegol是一种新的TNF抑制剂，为RA提供了额外的治疗选择。在这篇文章中，Ma博士和Choy博士考虑了certolizumab pegol的疗效，以及它可能适合RA军械库的位置。版权所有©2009 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
